MARKET

IGMS

IGMS

Igm Biosciences, Inc.
NASDAQ
1.250
-0.010
-0.79%
Opening 10:48 03/25 EDT
OPEN
1.260
PREV CLOSE
1.260
HIGH
1.260
LOW
1.221
VOLUME
20.48K
TURNOVER
--
52 WEEK HIGH
22.50
52 WEEK LOW
1.150
MARKET CAP
74.72M
P/E (TTM)
-0.3863
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IGMS last week (0317-0321)?
Weekly Report · 1d ago
Weekly Report: what happened at IGMS last week (0310-0314)?
Weekly Report · 03/17 09:21
Tracking Baker Brothers Portfolio - Q4 2024 Update
Seeking Alpha · 03/13 03:56
Weekly Report: what happened at IGMS last week (0303-0307)?
Weekly Report · 03/10 09:21
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts
TipRanks · 03/08 06:02
IGM Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/07 17:09
Morgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)
TipRanks · 03/07 13:51
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Aziyo Biologics (ELUT) and IGM Biosciences (IGMS)
TipRanks · 03/07 13:51
More
About IGMS
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Webull offers IGM Biosciences Inc stock information, including NASDAQ: IGMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IGMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IGMS stock methods without spending real money on the virtual paper trading platform.